fbpx
  • Home
  • Study Details
Open

PACES - Colorectal Cancer Prevention

To assess whether the combination of eflornithine and sulindac is effective in reducing the three-year event rate (high-risk adenomas and second primary colorectal cancers) in patients with previously treated Stage 0-III colon or rectal cancer.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female

Location

North Carolina (Edgecombe, Nash)

What will be asked of you

1 Optional Diet and Lifestyle Questionnaire

In-person visits : 18
Phone or online visits : 1
Total length of participation : 8 years total (3 years treatment + 5 years follow-up)

Looking for Specific Volunteers

Able to participate:

  • History of Stage 0-III colon or rectal cancer with primary resection 1 year previously
  • At least 30 days from completion of adjuvant chemo and RT.
  • Zubrod PS 0-1

Not eligible if:

  • Planned radiation therapy or additional chemotherapy, IV steroids, or if you are taking NSAID pain relievers regularly or on blood thinning medication.
  • Have uncontrolled hyperlibidemia or a history of heart attack, stroke, or coronary artery bypass surgery.
  • History of colon resection, mid-low rectal cancer, or recurrent or metastatic disease
  • Documented history of gastric/duodenal ulcer within last 12 months and/or current treatment or active symptoms of gastric/duodenal ulcer
  • Known history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or inflammatory bowel disease

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Devena Alston Johnson
UNC Hospitals - Nash

Study Topics

Cancer (Colorectal)

IRB Number

19-0685

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.